Severe Hypertriglyceridemia (SHTG) - Epidemiology Forecast - 2034

Severe Hypertriglyceridemia (SHTG) - Epidemiology Forecast - 2034

Key Highlights

Severe Hypertriglyceridemia (SHTG) diagnosed prevalence is expected to rise, driven by the increasing prevalence of Hypertriglyceridemia as well as a growing awareness of the disease.

Out of all diagnosed cases of Hypertriglyceridemia, Severe Hypertriglyceridemia (SHTG) constitutes just 5% of the total. When considering cases categorized by severity, moderate Hypertriglyceridemia (SHTG) had a higher prevalence than Severe Hypertriglyceridemia (SHTG) in the 7MM countries.

In 2022, the US accounted for the maximum diagnosed patient share of SHTG in the 7MM, i.e., 44%, followed by Japan accounting for around 16% of the total 7MM cases. Among the European countries higher number of cases were in Germany accounting for about 10% of the total 7MM cases.

During the forecast period (2023–2034), it is projected that the number of cases will rise in the 7MM countries, except for Germany and Japan. In these two countries, a decline in cases is expected due to their decreasing populations.

DelveInsight’s “Severe Hypertriglyceridemia (SHTG) – Epidemiology – 2034” report delivers an in-depth understanding of Severe Hypertriglyceridemia (SHTG), historical and forecasted epidemiology of Severe Hypertriglyceridemia (SHTG) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Severe Hypertriglyceridemia (SHTG) Disease Understanding

Severe Hypertriglyceridemia (SHTG) Overview

Severe hypertriglyceridemia (SHTG) presents a significant health concern characterized by exceptionally elevated levels of triglycerides in the bloodstream. Triglycerides, essential for providing energy to the body, become problematic when excessively high, posing risks for cardiovascular and metabolic disorders. While genetic predispositions, such as familial conditions, play a role in SHTG, lifestyle factors like dietary choices and obesity also contribute significantly. The absence of overt symptoms belies the potential severity of SHTG, as it lurks as a silent threat, heightening the risk of pancreatitis and cardiovascular complications. Recognizing the interplay of genetic and lifestyle influences underscores the importance of tailored interventions to mitigate these risks, emphasizing the need for personalized approaches in managing SHTG and safeguarding overall health.

Severe Hypertriglyceridemia (SHTG) Diagnosis

Severe hypertriglyceridemia (SHTG) is identified by elevated triglyceride levels exceeding 500 mg/dL, often accompanied by comprehensive lipid and metabolic evaluations. Diagnosing this condition can be intricate due to the absence of overt symptoms, potentially leading to oversight or misdiagnosis, particularly if healthcare providers concentrate solely on cholesterol parameters. Moreover, underlying genetic predispositions could be disregarded without a thorough assessment, potentially resulting in ineffective treatment strategies.

Further details related to disease and its diagnosis are provided in the report…

Severe Hypertriglyceridemia (SHTG) Epidemiology

The epidemiology section of the report utilizes a patient-centered model, to examine Severe Hypertriglyceridemia (SHTG), offering historical and projected data. This includes segmented information on Prevalent Cases of Hypertriglyceridemia (HTG), Diagnosed Prevalent Cases of Hypertriglyceridemia (HTG), Severity-specific Diagnosed Prevalent Cases of Hypertriglyceridemia (HTG), and Etiology-specific Diagnosed Prevalent Cases of Severe Hypertriglyceridemia (SHTG) in the United States, EU4 and the United Kingdom, and Japan from 2020 to 2034. Notably, the total diagnosed cases of Severe Hypertriglyceridemia (SHTG) in these regions were around 3,480,000 in 2022 and are anticipated to rise in the forecasted period.

As per our assessment, in 2022, nearly 155 million prevalent cases of Hypertriglyceridemia (HTG) were estimated in the 7MM. These cases are anticipated to increase by 2034.

The total diagnosed prevalent cases of HTG in the 7MM are expected to increase with a significant CAGR by 2034, from around 70 million cases in 2022 in the 7MM. The US accounted for the highest cases.

Among the European countries, Germany had the highest diagnosed prevalent population of SHTG, followed by the UK in 2022. On the other hand, Spain had the least diagnosed prevalent population of SHTG in the same year.

In Japan, among diagnosed prevalence cases of Hypertriglyceridemia (HTG), most cases were of moderate severity (5.6 million) in 2022. While mild cases and severe cases were around 5 million and 0.5 million respectively, in the same year.

The Severe Hypertriglyceridemia (SHTG) diagnosed cases were segmented based on etiology, as Primary SHTG and Secondary SHTG. Our estimate suggests that in the US higher number of cases were of secondary SHTG.

KOL Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Severe Hypertriglyceridemia (SHTG) evolving advancement in diagnosis, disease awareness, increasing cases, along with challenges, including Pulmonologists, HCPs, Physicians, and others.

Delveinsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Southern California Permanente Medical Group, West Los Angeles, US; University of California, Los Angeles, US; Pitié-Salpêtrière Hospital, Paris, France; Keio University School of Medicine, Tokyo, Japan; and others were contacted. Their opinion helps understand and validate current and future epidemiological patterns of Severe Hypertriglyceridemia (SHTG).

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Severe Hypertriglyceridemia (SHTG), explaining its causes, signs and symptoms, pathogenesis, and diagnosis.

Comprehensive insight into the epidemiology segments and forecasts, disease progression, and diagnostic guidelines has been provided.

The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Severe Hypertriglyceridemia (SHTG) Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Prevalent Cases of Hypertriglyceridemia (HTG)

Total Diagnosed Prevalent Cases of Hypertriglyceridemia (HTG)

Severity-specific Diagnosed Prevalent cases of Hypertriglyceridemia (HTG)

Etiology-specific Diagnosed Prevalent cases of Severe Hypertriglyceridemia (SHTG)

Severe Hypertriglyceridemia (SHTG) Report Key Strengths

Twelve Years Forecast

The 7MM Coverage

Severe Hypertriglyceridemia (SHTG) Epidemiology Segmentation

Severe Hypertriglyceridemia (SHTG) Report Assessment

Current Diagnostic Practices

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Severe Hypertriglyceridemia (SHTG)? What will be the growth opportunities across the 7MM concerning the patient population with Severe Hypertriglyceridemia (SHTG)?

What is the historical and forecasted Severe Hypertriglyceridemia (SHTG) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

What are the diagnosed prevalence rates in European countries and Japan? Why are Severe Hypertriglyceridemia (SHTG) patients not diagnosed efficiently?

Which etiology has a higher diagnosed prevalence of Severe Hypertriglyceridemia (SHTG)?

At what CAGR the population is expected to grow across the 7MM during the forecast period (2023–2034)?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the etiology-specific Severe Hypertriglyceridemia (SHTG) prevalent cases in varying geographies over the coming years.

A detailed overview of severity-specific cases of Hypertriglyceridemia (HTG) is an inclusion.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

The Severe Hypertriglyceridemia (SHTG) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.

Develop business strategies by understanding the trends shaping and driving the 7MM Severe Hypertriglyceridemia (SHTG) epidemiology forecast.

Frequently Asked Questions

1. How common is severe hypertriglyceridemia?

The prevalence of severe hypertriglyceridemia varies by population and region. It is more commonly seen in individuals with conditions like diabetes and obesity. The highest cases of SHTG were diagnosed in the US among the 7MM in 2022.

2. Can severe hypertriglyceridemia be prevented?

While genetic factors may play a role, adopting a healthy lifestyle can significantly reduce the risk of developing severe hypertriglyceridemia. This includes maintaining a balanced diet, staying physically active, avoiding excessive alcohol consumption, and managing underlying conditions like diabetes.

3. How does severe hypertriglyceridemia relate to cardiovascular health?

Elevated triglyceride levels are an independent risk factor for cardiovascular diseases. Severe hypertriglyceridemia can contribute to the development of atherosclerosis, which increases the risk of heart attacks, strokes, and other cardiovascular events.

4. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It's then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.